ZA200603221B - Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders - Google Patents
Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disordersInfo
- Publication number
- ZA200603221B ZA200603221B ZA200603221A ZA200603221A ZA200603221B ZA 200603221 B ZA200603221 B ZA 200603221B ZA 200603221 A ZA200603221 A ZA 200603221A ZA 200603221 A ZA200603221 A ZA 200603221A ZA 200603221 B ZA200603221 B ZA 200603221B
- Authority
- ZA
- South Africa
- Prior art keywords
- glyt
- triaza
- neurological
- inhibitors
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03024415 | 2003-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200603221B true ZA200603221B (en) | 2009-04-29 |
Family
ID=34486099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200603221A ZA200603221B (en) | 2003-10-23 | 2006-04-21 | Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders |
Country Status (19)
Country | Link |
---|---|
US (1) | US7189850B2 (no) |
EP (1) | EP1678177B1 (no) |
JP (1) | JP4490434B2 (no) |
KR (1) | KR100798161B1 (no) |
CN (1) | CN100467468C (no) |
AR (1) | AR046186A1 (no) |
AU (1) | AU2004283843B2 (no) |
BR (1) | BRPI0415833A (no) |
CA (1) | CA2543308C (no) |
CO (1) | CO5690643A2 (no) |
DE (1) | DE602004010419T2 (no) |
ES (1) | ES2297502T3 (no) |
IL (1) | IL174734A (no) |
MX (1) | MXPA06004305A (no) |
NO (1) | NO20061419L (no) |
RU (1) | RU2006117368A (no) |
TW (1) | TW200526662A (no) |
WO (1) | WO2005040166A1 (no) |
ZA (1) | ZA200603221B (no) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006235400A1 (en) * | 2005-04-11 | 2006-10-19 | Yale University | Method of treating schizophrenia prodrome |
DE102005038141A1 (de) * | 2005-08-12 | 2007-02-15 | Grünenthal GmbH | Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate |
CN101395142B (zh) | 2006-03-08 | 2012-03-28 | 弗·哈夫曼-拉罗切有限公司 | 4-氨基-1,5-取代的1,5-二氢-咪唑-2-酮 |
JP2009530247A (ja) * | 2006-03-16 | 2009-08-27 | グラクソ グループ リミテッド | N−フェニル−2−オキソ−1,4−ジアザスピロ[4.5]デカ−3−エン−1−イルアセトアミド誘導体およびグリシン輸送体阻害剤としてのそれらの使用 |
GB0607398D0 (en) * | 2006-04-12 | 2006-05-24 | Glaxo Group Ltd | Compounds |
US20070299072A1 (en) * | 2006-06-20 | 2007-12-27 | Wyeth | Kv1.5 potassium channel inhibitors |
JP2010517959A (ja) * | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | GlyT1トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用 |
US20100048656A1 (en) * | 2007-02-01 | 2010-02-25 | Nadia Mamoona Ahmad | Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
GB0701955D0 (en) * | 2007-02-01 | 2007-03-14 | Glaxo Group Ltd | Compounds |
EP2121690A1 (en) * | 2007-02-01 | 2009-11-25 | Glaxo Group Limited | Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
EP2121624A1 (en) * | 2007-02-01 | 2009-11-25 | Glaxo Group Limited | Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
GB0701985D0 (en) * | 2007-02-01 | 2007-03-14 | Glaxo Group Ltd | Compounds |
WO2008092877A2 (en) * | 2007-02-01 | 2008-08-07 | Glaxo Group Limited | 8-oxa-1, 4-diazaspiro [4,5] dec-3-en-1-yl and 1,4, 8-triazaspiro [4,5] dec- 3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders |
CN103936605B (zh) | 2007-05-31 | 2017-09-01 | 赛诺维信制药公司 | 苯基取代的环烷胺作为一元胺再摄取抑制剂 |
MX2009013745A (es) | 2007-07-03 | 2010-01-26 | Hoffmann La Roche | 4-imidazolinas y su uso como antidepresivos. |
US8420670B2 (en) | 2007-08-22 | 2013-04-16 | Abbott Laboratories | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy |
WO2009034062A1 (en) * | 2007-09-11 | 2009-03-19 | Glaxo Group Limited | Compounds which inhibit the glycine transporter and uses thereof in medicine |
US9413889B2 (en) * | 2007-09-18 | 2016-08-09 | Telecommunication Systems, Inc. | House number normalization for master street address guide (MSAG) address matching |
US7981904B2 (en) * | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
CN102083797B (zh) | 2008-04-01 | 2014-06-04 | Abbvie公司 | 四氢异喹啉、含有它们的药物组合物和它们在治疗中的用途 |
AU2010209816A1 (en) | 2009-01-27 | 2011-08-11 | F. Hoffmann-La Roche Ag | Aroylamino - and heteroaroylamino-substituted piperidines as GlyT-1 inhibitors |
TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
SI2632467T1 (sl) | 2010-10-25 | 2016-10-28 | G1 Therapeutics, Inc. | Inhibitorji CDK |
US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
JP2014521682A (ja) | 2011-08-05 | 2014-08-28 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミノクロマン、アミノチオクロマンおよびアミノ−1,2,3,4−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、ならびに治療におけるこれらの使用 |
WO2013072520A1 (en) | 2011-11-18 | 2013-05-23 | AbbVie Deutschland GmbH & Co. KG | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
EP2831080B1 (en) | 2012-03-29 | 2017-03-15 | Francis Xavier Tavares | Lactam kinase inhibitors |
JP2015157764A (ja) * | 2012-06-14 | 2015-09-03 | 大正製薬株式会社 | グリシントランスポーター阻害物質 |
LT2968290T (lt) | 2013-03-15 | 2019-12-10 | G1 Therapeutics Inc | Laikina normalių ląstelių apsauga chemoterapijos metu |
US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
EP3057958B1 (en) | 2013-10-17 | 2019-05-01 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
CA2924689A1 (en) | 2013-10-17 | 2015-04-23 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
SG11201605559VA (en) | 2014-01-06 | 2016-08-30 | Algomedix Inc | Trpa1 modulators |
US20150297608A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents |
EP3134406A1 (en) * | 2014-04-24 | 2017-03-01 | Dart Neuroscience (Cayman) Ltd | Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors |
US9550754B2 (en) | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016073420A1 (en) | 2014-11-05 | 2016-05-12 | Dart Neuroscience, Llc | Substituted azetidinyl compounds as glyt1 inhibitors |
BR112018015389B1 (pt) | 2016-03-17 | 2023-12-19 | F. Hoffmann-La Roche Ag | Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso |
WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
IL267795B2 (en) | 2017-01-06 | 2023-02-01 | G1 Therapeutics Inc | Combined treatment for cancer |
AU2018291026B2 (en) | 2017-06-29 | 2022-09-01 | G1 Therapeutics, Inc. | Morphic forms of GIT38 and methods of manufacture thereof |
CN112839657A (zh) | 2018-08-24 | 2021-05-25 | G1治疗公司 | 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成 |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI0921125T1 (en) * | 1997-12-05 | 2002-04-30 | F. Hoffmann-La Roche Ag | 1,3,8-Triazaspiro(4,5)decan-4-on derivatives |
WO2004072034A1 (en) * | 2003-02-17 | 2004-08-26 | F. Hoffmann-La Roche Ag | Piperidine-benzenesulfonamide derivatives |
-
2004
- 2004-10-14 ES ES04790408T patent/ES2297502T3/es active Active
- 2004-10-14 CA CA2543308A patent/CA2543308C/en not_active Expired - Fee Related
- 2004-10-14 WO PCT/EP2004/011552 patent/WO2005040166A1/en active IP Right Grant
- 2004-10-14 JP JP2006536007A patent/JP4490434B2/ja not_active Expired - Fee Related
- 2004-10-14 AU AU2004283843A patent/AU2004283843B2/en not_active Ceased
- 2004-10-14 CN CNB2004800309109A patent/CN100467468C/zh not_active Expired - Fee Related
- 2004-10-14 MX MXPA06004305A patent/MXPA06004305A/es active IP Right Grant
- 2004-10-14 KR KR1020067007791A patent/KR100798161B1/ko not_active IP Right Cessation
- 2004-10-14 BR BRPI0415833-4A patent/BRPI0415833A/pt not_active IP Right Cessation
- 2004-10-14 RU RU2006117368/04A patent/RU2006117368A/ru not_active Application Discontinuation
- 2004-10-14 EP EP04790408A patent/EP1678177B1/en not_active Not-in-force
- 2004-10-14 DE DE602004010419T patent/DE602004010419T2/de active Active
- 2004-10-18 US US10/967,534 patent/US7189850B2/en not_active Expired - Fee Related
- 2004-10-20 TW TW093131857A patent/TW200526662A/zh unknown
- 2004-10-21 AR ARP040103809A patent/AR046186A1/es not_active Application Discontinuation
-
2006
- 2006-03-28 NO NO20061419A patent/NO20061419L/no not_active Application Discontinuation
- 2006-04-03 IL IL174734A patent/IL174734A/en not_active IP Right Cessation
- 2006-04-21 ZA ZA200603221A patent/ZA200603221B/xx unknown
- 2006-05-03 CO CO06041532A patent/CO5690643A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1678177B1 (en) | 2007-11-28 |
CO5690643A2 (es) | 2006-10-31 |
KR100798161B1 (ko) | 2008-01-28 |
RU2006117368A (ru) | 2007-12-10 |
CA2543308A1 (en) | 2005-05-06 |
JP4490434B2 (ja) | 2010-06-23 |
US20050107373A1 (en) | 2005-05-19 |
JP2007509097A (ja) | 2007-04-12 |
CA2543308C (en) | 2012-03-06 |
DE602004010419T2 (de) | 2008-10-09 |
BRPI0415833A (pt) | 2007-01-02 |
NO20061419L (no) | 2006-07-14 |
CN100467468C (zh) | 2009-03-11 |
TW200526662A (en) | 2005-08-16 |
AU2004283843B2 (en) | 2010-04-22 |
IL174734A (en) | 2010-05-31 |
DE602004010419D1 (de) | 2008-01-10 |
CN1871238A (zh) | 2006-11-29 |
AR046186A1 (es) | 2005-11-30 |
EP1678177A1 (en) | 2006-07-12 |
MXPA06004305A (es) | 2006-06-05 |
ES2297502T3 (es) | 2008-05-01 |
US7189850B2 (en) | 2007-03-13 |
WO2005040166A1 (en) | 2005-05-06 |
AU2004283843A1 (en) | 2005-05-06 |
IL174734A0 (en) | 2006-08-20 |
KR20060076317A (ko) | 2006-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200603221B (en) | Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders | |
HK1090634A1 (en) | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases | |
HK1078858A1 (en) | Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders | |
ZA200705123B (en) | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | |
HK1079203A1 (en) | Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders | |
AU2002352483A1 (en) | Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders | |
IL184173A0 (en) | Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation | |
HK1089155A1 (en) | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | |
IL169091A0 (en) | Benzazepine derivatives for the treatment of neurological disorders | |
ZA200700223B (en) | Quinazolin-4-yl-piperidine and cinnolin-4-yl-peperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders | |
AU2003286567A8 (en) | Methods for the treatment of skin disorders | |
IL175055A0 (en) | Combinations useful for the treatment of neuronal disorders | |
PL374700A1 (en) | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders | |
IL184353A0 (en) | [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted-phenyl)methanone derivatives as glycine transporter 1 (glyt-1)inhibitors for the treatment of neurological and neuropsychiatric disorders | |
IL183656A0 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
EP1664051A4 (en) | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USING SAME FOR TREATING PROLIFERATION DISORDERS | |
ZA200410409B (en) | Use of thio-oxindole derivatives in treatment of hormonerelated conditions | |
IL165394A0 (en) | Use of thio-oxindole derivatives in treatment of skin disorders | |
AU2003228819A8 (en) | Combinations for the treatment of inflammatory skin disorders | |
EP1680145A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
IL172018A0 (en) | Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases | |
GB0321384D0 (en) | Pteridine derivatives for the treatment of septic shock and TNF-alpha- related diseases | |
IL162154A0 (en) | Prostagandin composition for the treatment of erectile dysfunction | |
PL375564A1 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
AU2003253130A1 (en) | Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders |